Literature DB >> 17033159

Hearing in patients with intracanalicular vestibular schwannomas.

Per Caye-Thomasen1, Thomas Dethloff, Søren Hansen, Sven-Eric Stangerup, Jens Thomsen.   

Abstract

This paper reports data on the spontaneous course of hearing in 156 patients with purely intracanalicular vestibular schwannomas. The mean pure tone average (PTA) was 51 dB HL and the mean speech discrimination score (SDS) 60% at diagnosis. The risk of a significant subsequent hearing loss (>or=10 dB PTA or >or=10% SDS) was 54% during 4.6 years of observation. Patients with normal speech discrimination at diagnosis had a significantly smaller risk of loosing hearing. The hearing loss at diagnosis and during observation was not related to age, gender, diagnostic tumor size, tumor- induced expansion of the internal auditory canal or tumor sublocalization (fundus, central or porus). However, the loss of PTA was smaller in shrinking tumors and the PTA deterioration rate correlated with the volumetric tumor growth rate. After 4.6 years observation, the PTA had increased by 14 dB to 65 dB HL, and the SDS reduced by 17% to 43%. The proportion of patients eligible for hearing preservation treatment as determined by word recognition score class I (70-100% SDS) was reduced to 28% (a 44% reduction), and by AAO-HNS class A to 9% (a 53% reduction). Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 17033159     DOI: 10.1159/000096152

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  22 in total

1.  Outcome on hearing and facial nerve function in microsurgical treatment of small vestibular schwannoma via the middle cranial fossa approach.

Authors:  Christian Ginzkey; Matthias Scheich; Wilma Harnisch; Verena Bonn; Desiree Ehrmann-Müller; Wafaa Shehata-Dieler; Robert Mlynski; Rudolf Hagen
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06-22       Impact factor: 2.503

2.  Systematic Review of Hearing Preservation in Observed Vestibular Schwannoma.

Authors:  Martin Reznitsky; Per Cayé-Thomasen
Journal:  J Neurol Surg B Skull Base       Date:  2019-03-01

3.  Determining benchmarks in hearing preservation surgery for vestibular schwannoma.

Authors:  Michael B Gluth; John D Day; John L Dornhoffer
Journal:  J Neurol Surg B Skull Base       Date:  2012-08

4.  Long-term hearing preservation after microsurgical excision of vestibular schwannoma.

Authors:  Erika Ann Woodson; Ryan Douglas Dempewolf; Samuel Paul Gubbels; Aaron Thomas Porter; Jacob Jay Oleson; Marlan Rex Hansen; Bruce Jay Gantz
Journal:  Otol Neurotol       Date:  2010-09       Impact factor: 2.311

5.  The natural history of vestibular schwannoma growth-prospective 40-year data from an unselected national cohort.

Authors:  Martin Reznitsky; Mette Marie Babiel Schmidt Petersen; Niels West; Sven-Eric Stangerup; Per Cayé-Thomasen
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

6.  Cochlear obliteration after translabyrinthine vestibular schwannoma surgery.

Authors:  Caroline Beutner; Christian Mathys; Bernd Turowski; Jörg Schipper; Thomas Klenzner
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-11       Impact factor: 2.503

7.  [Hearing results after middle fossa removal of small (T1/T2) vestibular schwannomas].

Authors:  M Scheich; D Ehrmann-Müller; W Shehata-Dieler; R Hagen
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

8.  Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells.

Authors:  Vitor Y R Soares; Nadia A Atai; Takeshi Fujita; Sonam Dilwali; Sarada Sivaraman; Lukas D Landegger; Fred H Hochberg; Carlos A P C Oliveira; Fayez Bahmad; Xandra O Breakefield; Konstantina M Stankovic
Journal:  Neuro Oncol       Date:  2016-05-18       Impact factor: 12.300

Review 9.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

10.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.